Tumours that are ER−, PR−, and HER2+ are linked to the HER2-enriched molecular subtype, and those that are ER−, PR−, and HER2− are considered to have triple-negative breast cancer (TNBC) which overlaps with basal-like tumours [12,13]. Here, ERBB2 is linked to neoplasm.